1.Ali H, al-Sarraf M. Chemotherapy in advanced nasopharyngeal cancer. Oncology (Williston Park). 2000;14(8):1223–30; discussion 32–7, 39–42.
2.Li Q, Ding C, Chen C, Zhang Z, Xiao H, Xie F, et al. miR–224 promotion of cell migration and invasion by targeting Homeobox D 10 gene in human hepatocellular carcinoma. Journal of gastroenterology and hepatology. 2014;29(4):835–42.
3.Taylor MA, Schiemann WP. Therapeutic Opportunities for Targeting microRNAs in Cancer. Molecular and cellular therapies. 2014;2(30):1–13.
4.Khoury S, Tran N. Circulating microRNAs: potential biomarkers for common malignancies. Biomarkers in medicine. 2015;9(2):131–51.
5.Sabarimurugan S, Kumarasamy C, Baxi S, Devi A, Jayaraj R. Systematic review and meta-analysis of prognostic microRNA biomarkers for survival outcome in nasopharyngeal carcinoma. PloS one. 2019;14(2):e0209760.
6.Zheng J, Wang G, Yang GY, Wang D, Luo X, Chen C, et al. Induction chemotherapy with nedaplatin with 5-FU followed by intensity-modulated radiotherapy concurrent with chemotherapy for locoregionally advanced nasopharyngeal carcinoma. Japanese journal of clinical oncology. 2010;40(5):425–31.
7.Yi Z, Fu Y, Zhao S, Zhang X, Ma C. Differential expression of miRNA patterns in renal cell carcinoma and nontumorous tissues. Journal of cancer research and clinical oncology. 2010;136(6):855–62.
8.Sofocleous CT, Garg S, Petrovic LM, Gonen M, Petre EN, Klimstra DS, et al. Ki–67 is a prognostic biomarker of survival after radiofrequency ablation of liver malignancies. Annals of surgical oncology. 2012;19(13):4262–9.
9.Gunia S, Kakies C, Erbersdobler A, Hakenberg OW, Koch S, May M. Expression of p53, p21 and cyclin D1 in penile cancer: p53 predicts poor prognosis. Journal of clinical pathology. 2012;65(3):232–6.
10.Jaiswal R, Raymond Grau GE, Bebawy M. Cellular communication via microparticles: role in transfer of multidrug resistance in cancer. Future oncology. 2014;10(4):655–69.
11.Gold B, Cankovic M, Furtado LV, Meier F, Gocke CD. Do circulating tumor cells, exosomes, and circulating tumor nucleic acids have clinical utility? A report of the association for molecular pathology. The Journal of molecular diagnostics: JMD. 2015;17(3):209–24.
12.Navarro A, Diaz T, Tovar N, Pedrosa F, Tejero R, Cibeira MT, et al. A serum microRNA signature associated with complete remission and progression after autologous stem-cell transplantation in patients with multiple myeloma. Oncotarget. 2015;6(3):1874–83.
13.Rocci A, Hofmeister CC, Geyer S, Stiff A, Gambella M, Cascione L, et al. Circulating miRNA markers show promise as new prognosticators for multiple myeloma. Leukemia. 2014;28(9):1922–6.
14.Kapinas K, Kessler C, Ricks T, Gronowicz G, Delany AM. miR–29 modulates Wnt signaling in human osteoblasts through a positive feedback loop. The Journal of biological chemistry. 2010;285(33):25221–31.
15.Tsuchiya N, Izumiya M, Ogata-Kawata H, Okamoto K, Fujiwara Y, Nakai M, et al. Tumor suppressor miR–22 determines p53-dependent cellular fate through post-transcriptional regulation of p21. Cancer research. 2011;71(13):4628–39.
16.Kim SW, Ramasamy K, Bouamar H, Lin AP, Jiang D, Aguiar RC. MicroRNAs miR–125a and miR–125b constitutively activate the NF-kappaB pathway by targeting the tumor necrosis factor alpha-induced protein 3 (TNFAIP3, A20). Proceedings of the National Academy of Sciences of the United States of America. 2012;109(20):7865–70.
17.Zhu Y, Lu Y, Zhang Q, Liu JJ, Li TJ, Yang JR, et al. MicroRNA–26a/b and their host genes cooperate to inhibit the G1/S transition by activating the pRb protein. Nucleic acids research. 2012;40(10):4615–25.
18.Chen L, Xiao H, Wang ZH, Huang Y, Liu ZP, Ren H, et al. miR–29a suppresses growth and invasion of gastric cancer cells in vitro by targeting VEGF-A. BMB reports. 2014;47(1):39–44.
19.Han HS, Son SM, Yun J, Jo YN, Lee OJ. MicroRNA–29a suppresses the growth, migration, and invasion of lung adenocarcinoma cells by targeting carcinoembryonic antigen-related cell adhesion molecule 6. FEBS letters. 2014;588(20):3744–50.
20.Yang Q, Wang Y, Lu X, Zhao Z, Zhu L, Chen S, et al. miRNA–125b regulates epithelial-mesenchymal transition via targeting Sema4C in paclitaxel-resistant breast cancer cells. Oncotarget. 2015;6(5):3268–79.
21.Haemmig S, Baumgartner U, Gluck A, Zbinden S, Tschan MP, Kappeler A, et al. miR–125b controls apoptosis and temozolomide resistance by targeting TNFAIP3 and NKIRAS2 in glioblastomas. Cell death & disease. 2014;5:e1279.
22.Huang K, Fu J, Zhou W, Li W, Dong S, Yu S, et al. MicroRNA–125b regulates osteogenic differentiation of mesenchymal stem cells by targeting Cbfbeta in vitro. Biochimie. 2014;102:47–55.
23.Chaudhuri AA, So AY, Mehta A, Minisandram A, Sinha N, Jonsson VD, et al. Oncomir miR–125b regulates hematopoiesis by targeting the gene Lin28A. Proceedings of the National Academy of Sciences of the United States of America. 2012;109(11):4233–8.
24.Tsang FH, Au SL, Wei L, Fan DN, Lee JM, Wong CC, et al. Long non-coding RNA HOTTIP is frequently up-regulated in hepatocellular carcinoma and is targeted by tumour suppressive miR–125b. Liver international: official journal of the International Association for the Study of the Liver. 2015;35(5):1597–606.
25.Wu D, Ding J, Wang L, Pan H, Zhou Z, Zhou J, et al. microRNA–125b inhibits cell migration and invasion by targeting matrix metallopeptidase 13 in bladder cancer. Oncology letters. 2013;5(3):829–34.
26.Fukumoto I, Hanazawa T, Kinoshita T, Kikkawa N, Koshizuka K, Goto Y, et al. MicroRNA expression signature of oral squamous cell carcinoma: functional role of microRNA–26a/b in the modulation of novel cancer pathways. British journal of cancer. 2015;112(5):891–900.
27.Li J, Li X, Kong X, Luo Q, Zhang J, Fang L. MiRNA–26b inhibits cellular proliferation by targeting CDK8 in breast cancer. International journal of clinical and experimental medicine. 2014;7(3):558–65.
28.Zhao N, Wang R, Zhou L, Zhu Y, Gong J, Zhuang SM. MicroRNA–26b suppresses the NF-kappaB signaling and enhances the chemosensitivity of hepatocellular carcinoma cells by targeting TAK1 and TAB3. Molecular cancer. 2014;13:35.
29.Zhang C, Tong J, Huang G. Nicotinamide phosphoribosyl transferase (Nampt) is a target of microRNA–26b in colorectal cancer cells. PloS one. 2013;8(7):e69963.
30.Absalon S, Kochanek DM, Raghavan V, Krichevsky AM. MiR–26b, upregulated in Alzheimer’s disease, activates cell cycle entry, tau-phosphorylation, and apoptosis in postmitotic neurons. The Journal of neuroscience: the official journal of the Society for Neuroscience. 2013;33(37):14645–59.
31.Martens-Uzunova ES, Jalava SE, Dits NF, van Leenders GJ, Moller S, Trapman J, et al. Diagnostic and prognostic signatures from the small non-coding RNA transcriptome in prostate cancer. Oncogene. 2012;31(8):978–91.
32.Volinia S, Calin GA, Liu CG, Ambs S, Cimmino A, Petrocca F, et al. A microRNA expression signature of human solid tumors defines cancer gene targets. Proceedings of the National Academy of Sciences of the United States of America. 2006;103(7):2257–61.
33.Schaefer A, Jung M, Mollenkopf HJ, Wagner I, Stephan C, Jentzmik F, et al. Diagnostic and prognostic implications of microRNA profiling in prostate carcinoma. International journal of cancer. 2010;126(5):1166–76.